Reuters logo
5 months ago
BRIEF-Redhill biopharma reports first patient dosed in open-label extension study
March 21, 2017 / 1:36 PM / 5 months ago

BRIEF-Redhill biopharma reports first patient dosed in open-label extension study

March 21 (Reuters) - Redhill Biopharma Ltd:

* Redhill Biopharma announces first patient dosed in the open-label extension study to the phase iii study with rhb-104 for crohn’s disease

* Redhill Biopharma Ltd- second independent DSMB meeting for map us phase iii study is expected in mid-2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below